Treatment of obesity and obesity-related disorders
US-2024277813-A1 · Aug 22, 2024 · US
Satiation peptide administration
US9492505B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9492505-B2 |
| Application number | US-201013145660-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 21, 2010 |
| Priority date | Jan 21, 2009 |
| Publication date | Nov 15, 2016 |
| Grant date | Nov 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inducing satiation in a subject comprising applying a therapeutically effective dose of a satiation gut peptide to a tongue in a mouth of a subject, wherein the satiation gut peptide is contained within a lozenge, wherein the lozenge is in the form of a dissolvable planar sheet, wherein said satiation gut peptide is unmodified Peptide YY (PYY), and wherein the application of the dissolvable planar sheet to the tongue does not substantially change the concentration of the satiation peptide in the plasma of the subject. 2. A method of inducing satiation in a subject comprising applying a therapeutically effective dose of a satiation gut peptide to a tongue in a mouth of a subject, wherein the satiation gut peptide is contained within a lozenge, wherein the lozenge is in the form of a dissolvable planar sheet, wherein said satiation gut peptide consists essentially of Peptide YY (PYY), and wherein the application of the dissolvable planar sheet to the tongue does not substantially change the concentration of the satiation peptide in the plasma of the subject. 3. The method of claim 2 , wherein the satiation gut peptide is delivered to the subject prior to eating. 4. A method of treating obesity of a subject comprising delivering a therapeutically effective dose of a satiation gut peptide to a tongue in a mouth of said subject via a lozenge loaded with the satiation gut peptide, wherein the lozenge is in the form of a dissolvable planar sheet, wherein said satiation gut peptide is unmodified Peptide YY (PYY), and wherein the therapeutically effective dose does not substantially change the concentration of the satiation peptide in plasma of the subject. 5. The method of claim 4 , wherein the satiation gut peptide is delivered to the subject prior to eating. 6. A method of treating obesity of a subject comprising delivering a therapeutically effective dose of a satiation gut peptide to a tongue in a mouth of said subject via a lozenge loaded with the satiation gut peptide, wherein the lozenge is in the form of a dissolvable planar sheet, wherein said satiation gut peptide consists essentially of Peptide YY (PYY), and wherein the therapeutically effective dose does not substantially change the concentration of the satiation peptide in the plasma of the subject. 7. The method of claim 6 , wherein the satiation gut peptide is delivered to the subject prior to eating.
Assignees
Inventors
Classifications
Antidepressants · CPC title
Anorexiants; Antiobesity agents · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
Anxiolytics · CPC title
- A61K38/22Primary
Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9492505B2 cover?
- Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.
- Who is the assignee on this patent?
- Zolotukhin Sergei, Acosta Andres, Univ Florida
- What technology area does this patent fall under?
- Primary CPC classification A61K38/22. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).